Company

Vivatides Therapeutics

Vivatides Therapeutics develops oligonucleotide therapies and delivery technology targeting tissues beyond the liver.

About

Founded in 2025 in Hong Kong, Vivatides Therapeutics develops a preclinical platform for extra-hepatic oligonucleotide delivery and therapeutic programs using ASO and siRNA approaches. In April 2026, it raised USD 54 million in Series A funding led by Qiming Venture Partners, with HighLight Capital, TF Capital, and Apricot Capital participating. The company may generate revenue through licensing, partnerships, sponsored research, and future product development.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in